← Back to Search

Resiliency Training for Neurofibromatosis

Waitlist Available
Led By Ana-Maria Vranceanu, PhD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Has a diagnosis of NF1 or NF2 and is between the ages of 12-17
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up 0 weeks, 8 weeks, 6 months,12 months
Awards & highlights

Study Summary

This trial is testing two stress and symptom management programs for adolescents with Neurofibromatosis 1 and 2. The programs are 8 weeks long and done in a group setting.

Who is the study for?
Adolescents aged 12-17 with Neurofibromatosis type 1 or 2, who can understand and consent to the study in English with parental approval. Participants should have difficulties managing stress and NF symptoms but no major unrelated medical issues, recent changes in antidepressants, or recent cognitive therapy.Check my eligibility
What is being tested?
The trial is testing two different resiliency training programs delivered through live video over eight weeks to see how they help adolescents with Neurofibromatosis manage stress and symptoms related to their condition.See study design
What are the potential side effects?
Since the interventions are non-medical stress management programs, there may not be direct side effects like those associated with medications; however, participants might experience emotional discomfort while discussing personal topics.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am diagnosed with NF1 or NF2 and am between 12-17 years old.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 weeks, 8 weeks, 6 months,12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 weeks, 8 weeks, 6 months,12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Physical Health Quality of Life
Change in Psychological Health Quality of Life
Secondary outcome measures
Environmental Quality of Life
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Stress and Symptom Management Program 1Experimental Treatment1 Intervention
Group II: Stress and Symptom Management 2Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,941 Previous Clinical Trials
13,200,468 Total Patients Enrolled
2 Trials studying Neurofibromatosis
151 Patients Enrolled for Neurofibromatosis
United States Department of DefenseFED
866 Previous Clinical Trials
327,305 Total Patients Enrolled
1 Trials studying Neurofibromatosis
19 Patients Enrolled for Neurofibromatosis
Ana-Maria Vranceanu, PhDPrincipal Investigator - Massachusetts General Hospital
Massachusetts General Hospital
20 Previous Clinical Trials
1,886 Total Patients Enrolled
2 Trials studying Neurofibromatosis
151 Patients Enrolled for Neurofibromatosis

Media Library

Stress and Symptom Management Program 1 Clinical Trial Eligibility Overview. Trial Name: NCT03873610 — N/A
Neurofibromatosis Research Study Groups: Stress and Symptom Management Program 1, Stress and Symptom Management 2
Neurofibromatosis Clinical Trial 2023: Stress and Symptom Management Program 1 Highlights & Side Effects. Trial Name: NCT03873610 — N/A
Stress and Symptom Management Program 1 2023 Treatment Timeline for Medical Study. Trial Name: NCT03873610 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants being sought for this research endeavor?

"Affirmative, the information located on clinicaltrials.gov verify that this medical trial is actively enrolling patients. The listing was initially posted to the directory on December 15th 2019 and has since been revised on September 7th 2021. 200 participants are needed from 1 different location for the study to be a success."

Answered by AI

Who can participate in this medical research?

"This medical trial is seeking two-hundred patients with neurofibromatoses between the ages of twelve and seventeen. Eligibility demands that one must have been diagnosed NF1 or NF2, be able to comprehend theinformed consent process/assent in English, receive parental approval for participation, possess a minimum 3rd grade reading fluency in English, and struggle to cope with stress induced by their condition."

Answered by AI

What is the desired outcome of this clinical experiment?

"This medical research will measure Change in Psychological Health Quality of Life over a 0-week, 8-week, 6 month and 12 month period as its primary outcome indicator. The secondary outcomes tracked include Pain Interference Index (PII), Patient Health Questionnaire (PHQ-9) Adolescent Version for Depression symptoms, and Generalized Anxiety Disorder (GAD-7) scores to track levels of anxiety."

Answered by AI

For what age demographic is enrollment accepted in this experiment?

"This scientific research is open to participants aged 12 and above, but below 17 years old."

Answered by AI

How many individuals are involved in the experiment at maximum capacity?

"Affirmative, the information available on clinicaltrials.gov shows that this research project is currently recruiting. Initially posted in December 2019 and last modified on September 2021, it requires 200 participants to be enrolled at 1 location."

Answered by AI
~37 spots leftby May 2025